ClinicalTrials.gg
RecruitingNCT07207070Updated Dec 30, 2025

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

A Phase 3 interventional study of JS105 and Dalpiciclib in Breast Cancer, sponsored by Risen (Suzhou) Pharma Tech Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Risen (Suzhou) Pharma Tech Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
385th of 1,520
312 · median 120
Started
2025
with 236 others
Phase 3
331 of 1,930
120 open now
Primary completion
2029-05
later than 950 of 1,064 live
Registered
1,664th of 1,930
by date

Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 385th largest by planned enrollment of the 1,520 interventional ones that give a count, is one of 237 that started in 2025, is one of 331 in phase 3, reaches primary completion later than 950 of the 1,064 other live ones, and was the 1,664th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

863 more — sign in →

All 868 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,930 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of signing the consent form, age must be between 18 and 75 years old, males and females;
  2. Patients with unresectable PIK3CA-mutated HR-positive -negative recurrent or breast cancer;
  3. Consent to provide tumour tissue or blood samples to determine the PIK3CA mutation status;
  4. 0 or 1;
  5. At least one as per v1.1, or only bone metastases;
  6. Expected survival≥12 weeks;
  7. Good organ function;
  8. Patients voluntarily join the study and sign the ;

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with fulvestrant or PI3K/AKT/mTOR inhibitors;
  2. Presence of untreated or active central nervous system (CNS) ;
  3. Presence of significant clinical symptoms or uncontrolled pleural effusion, ascites, or pericardial effusion that require repeated drainage (once a month or more frequently);
  4. Untreated spinal cord compression, or previously treated spinal cord compression without clinical evidence of disease stability for at least 4 weeks prior to the first study treatment;
  5. Have received other anti-tumor treatment within 2-4 weeks before the first dose;
  6. Toxicities from prior anti-tumor therapy that have not recovered to ≤ Grade 1;
  7. Coexisting uncontrolled accompanying diseases, including but not limited to: history of type I diabetes or uncontrolled type II diabetes, presence of active infection, severe cardiovascular or cerebrovascular diseases, etc;
  8. Having another malignant tumour within the last 5 years prior to the first study treatment, except for that are expected to be cured after treatment;
  9. Active or C;
  10. Known to any of the study drugs or their ;
  11. Pregnant or breastfeeding females;
  12. Presence of other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participation in the study, affect treatment compliance, or interfere with study results, as judged by the investigator;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    JS105+Dalpiciclib+Fulvestrant

    Patients will receive JS105, Dalpiciclib and Fulvestrant.

    Drug: JS105 · Drug: Dalpiciclib · Drug: Fulvestrant 50 Mg/mL Intramuscular Solution

  • Active comparator
    Dalpiciclib+Fulvestrant

    Patients will receive Dalpiciclib and Fulvestrant.

    Drug: Dalpiciclib · Drug: Fulvestrant 50 Mg/mL Intramuscular Solution

Interventions

  • DrugJS105

    Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.

  • Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle;

  • DrugFulvestrant 50 Mg/mL Intramuscular Solution

    Drug page: Fulvestrant

    Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.

06

What researchers measure

Primary outcomes

  1. Blind Independent Central Review (BICR) assessed PFS based on RECIST v1.1 (BICR-PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first).

    Time frame: Up to 3.5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Up to 5 years

  2. Investigator-assessed Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first).

    Time frame: Up to 3.5 years

  3. 1-year and 2-year Progression-Free Survival (PFS) rate

    1-year and 2-year Progression-Free Survival (PFS) rate

    Time frame: Up to 3.5 years

  4. Objective Response Rate (ORR)

    Objective Response Rate (ORR) as Assessed by Investigator or BICR according to RECIST v1.1

    Time frame: Up to 5 years

  5. Duration of Objective Response (DOR)

    Duration of Objective Response (DOR) as Assessed by Investigator or BICR according to RECIST v1.1

    Time frame: Up to 5 years

  6. Disease Control Rate(DCR)

    Disease Control Rate(DCR) as Assessed by Investigator or BICR according to RECIST v1.1

    Time frame: Up to 5 years

  7. Adverse Event

    Collect Serious Adverse Events (SAEs) and Adverse Events (AEs) from the time of signing the Informed Consent Form (ICF) until the safety follow-up visit.Evaluate the safety of the investigational drug.

    Time frame: Up to 5 years

  8. Plasma Concentration of JS105

    Collect JS105 PK sample to evaluate the blood drug concentration after the administration of JS105.

    Time frame: Up to 3.5 years

07

Study locations

2 of 2 sites recruiting
  • Chinese Acadamy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing Municipality 100021, China
    Recruiting
    • Min Yan, Ph.D · Contactym200678@126.com · 0371-65588404
    • Min Yan, Ph.D · Principal investigator
  • Henan Provincial Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2029, 42 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 42 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Nov 12, 2025
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2030
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07207070
Lead sponsor
Risen (Suzhou) Pharma Tech Co., Ltd.
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Nov 12, 2025
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Dec 30, 2025

Study contacts

Qianna Zhan, Master
Contact
zhan@junshipharma.com
13526615319
Huiyu Lan, Master
Contact
huiyu_lan@junshipharma.com
15000239047
Xianming Luo, Doctor
study director · Medical Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion